The role of entecavir in the treatment of chronic hepatitis B

Therapeutics and Clinical Risk Management

Volumn 3, Issue 6, 2007, Pages 1077-1086

  Dimou, Evangelini ^a   Papadimitropoulos, Vasilios ^a   Hadziyannis, Stephanos J ^a  

^a HENRY DUNANT HOSPITAL   (Greece)

Author keywords

Chronic hepatitis B; Entecavir; HBV resistance; Nucleoside analogue

Indexed keywords

ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ENTECAVIR; GLYCINE; HEPATITIS B(E) ANTIGEN; ISOLEUCINE; LAMIVUDINE; PEGINTERFERON ALPHA2A; PLACEBO; SERINE; TELBIVUDINE; THREONINE; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; BIOCHEMISTRY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DNA DETERMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HISTOPATHOLOGY; HUMAN; INHIBITION KINETICS; LIVER PARENCHYMA; MONOTHERAPY; OPTIMAL DRUG DOSE; POLYMERASE CHAIN REACTION; REMISSION; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 38049171346     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. Brunelle MN, Jacquard AC, Pichoud C, et al. 2005. Susceptibility to anti-virals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology, 41:1391-8.
2. Chang TT, Gish RG, Hadziyannis SJ, et al. 2005. A dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patients. Gastroenterology, 129:1198-209.
3. Chang TT, Gish RG, De Man R, et al. 2006a. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med, 354:1001-10.
4. Chang TT, Chao YC, Kaymakoglou S, et al. 2006b. Entecavir maintained virologic suppression through 3 years of treatment in antiviral-naïve HBeAg(+) patients (ETV 022/901). Hepatology, 44:229A.
5. Colonno RJ, Rose RE, Baldick CJ, et al. 2006a. High barrier of resistance results in no emergence of entecavir resistance in nucleoside-naïve subjects during the first two years of therapy. J Hepatol, 44:S182.
6. Colonno RJ, Rose RE, Pokornowski K, et al. 2006b. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naive patients while resistance emergence increases over time in lamivudine refractory patients. Hepatology, 44:229A.
7. Cooksley H, Hou JL, Vitek L, et al. 2006. Impact of nucleoside treatment on antiviral T-cell reactivity in chronic hepatitis B: major differences depending on early viral suppression, HBeAg status and HBV genotype. Hepatology, 44:547A.
8. De Man RA, Leonieke MMW, Nevens F, et al. 2001. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology, 34:578-82.
9. Di Marco V, Marzano A, Lampertico P, et al. 2004. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to Lamivudine. Hepatology, 40:883-91.
10. Dienstang JL, Schiff ER, Wright TL, et al. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United states. N Engl J Med, 341:1256-63.
11. Dienstag JL, Goldi RD, Heathcote EJ, et al. 2003. Histological outcome during long-term lamivudine therapy. Gastroenterology, 124:105-17.
12. Fung SK, Andreone P, Han SH, et al. 2005. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol, 43:937-43.
13. Fung SK, Chae HB, Fontana RJ, et al. 2006. Virological response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol, 44:283-90.
14. Gish RG, Chang TT, De Man R, et al. 2005. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconvertion through 96 weeks of treatment in HBeAg(+) chronic hepatitis B patients (Study ETV-022). Hepatology, 42:267A-268A.
15. Hadziyannis SJ, Bramou T, Makris A, et al. 1990. Interferon a-2b treatment of HBeAg negative/serum HBV-DNA positive chronic active hepatitis type B. J Hepatol, 11(Suppl 1):S113-36.
16. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 348:800-7.
17. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2005a. Long-term therapy with Adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med, 352:2673-81.
18. Hadziyannis SJ, Tassopoulos NC, Chang TT, et al. 2005b. Long-term Adefovir dipivoxil treatment induces regression of liver fibrosis in patients with HBeAg-negative chronic hepatitis B: results after 5 years of therapy. Hepatology, 42:754A.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. 2006. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology, 131:1743-51.
20. Lai CL, Chien RN, Leung NWY, et al. 1998. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med, 339:61-8.
21. Lai CL, Rosmawati M, Lao J, et al. 2002. Entecavir is superior than lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology, 123:1831-8.
22. Lai CL, Lim SG, Brown NA, et al. 2004. A dose-finding study of once-daily oral Telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology, 40:719-26.
23. Lai CL, Leung N, Teo EK, et al. 2005a. A 1-year trial of Telbivudine, Lamivudine, and the combination in patients with hepatitis Be antigen-positive chronic hepatitis B. Gastroenterology, 129:528-36.
24. Lai CL, Gane E, Liaw YF, et al. 2005b. Telbivudine (LDT) vs. Lamivudine for chronic hepatitis B: first-year results from the international phase III globe trial. Hepatology, 42:748A.
25. Lai CL, Gane E, Hsu CW, et al. 2006a. Two-years results from the globe trial in patients with hepatitis B: greated clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine. Hepatology, 44:222A.
26. Lai CL, Shouval D, Lok AS, et al. 2006b. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 354:1011-20.
27. Lampertico P, Vigano M, Manenti E, et al. 2005. Five years of sequential LAM to LAM + ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma. Hepatology, 42:582A.
28. Lampertico P, Vigano M, Iavarone M, et al. 2006. Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years. Hepatology, 44:556A.
29. Lau GKK, Piratvisuth T, Luo KX, et al. 2005. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med, 352:2682-95.
30. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med, 337:1733-45.
31. Leung NWY, Lai CL, Chang TT, et al. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy. Hepatology, 33:1527-32.
32. Liaw YF, Leung NWY, Chang TT, et al. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology, 119:172-80.
33. Liaw YF, Sung JJY, Chow WC, et al. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521-31.
34. Lok AS, Heathcote EJ, Hoofnagle JH. 2001. Management of hepatitis B: 2000 summary of a workshop. Gastroenterology, 120:1828-53.
35. Lok ASF, Lai CL, Leung N, et al. 2003. Long-term safety of Lamivudine treatment in patients with chronic hepatitis B. Gastroenterology, 125:1714-22.
36. Maddrey WC. 2000. Hepatitis B: an important public health issue. J Med Virol, 61:362-6.
37. Manesis E. and Hadziyannis S. 2001. Inteferon α treatment and retreatment of hepatitis B e negative chronic hepatitis B. Gastroenterology, 321:101-9.
38. Marcellin P, Chang TT, Lim SG, et al. 2003. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitisB. N Engl J Med, 348:808-16.
39. Marcellin P, Lau GKK, Bonino F, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone and the two combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med, 351:1206-17.
40. Marcellin P, Chang TT, Lim SG, et al. 2005. Increasing serologic, virologic and biochemical response over time to Adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients. J Hepatol, 42(2): S31-2.
41. Marcellin P, Lau GKK, Farci P, et al. 2006. The majority of patients with HBeAg-negative chronic hepatitis B treated with Peginterferon alpha-2a (40KD) [PEGASYS] sustain responses 2 years post-treatment. J Hepatol, 44(2):S275.
42. Niederaou C, Heintges T, Lange S, et al. 1996. Long term follow up of HBeAg positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med, 334:1422-7.
43. Papatheodoridis GV, Manesis E, Hadziyannis SJ. 2001. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol, 34:306-13.
44. Papatheodoridis GV, Dimou E, Laras A, et al. 2002. Course of virological breakthroughs under long-term lamivudine in HBeAg negative precore mutant HBV liver disease. Hepatology, 36:219-26.
45. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. 2005. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology, 42:121-9.
46. Peters MG, Hann HW, Martin P, et al. 2004. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitisB. Gastroenterology, 126:91-101.
47. Rapti IN, Dimou E, Mitsoula P, Hadziyannis SJ. 2007. Combination of adefovir dipivoxil with lamivudine vs adefovir alone in lamivudine-resistant HBeAg-negative chronic hepatitis B patients. Hepatology, 45:307-13.
48. Schiff E, Lee WM, Chao YC, et al. 2005. Efficacy and safety of entecavir (ETV) and lamivudine (LVD) in compensated, cirrhotic patients with chronic hepatitis B. Hepatology, 42:583A.
49. Sherman M, Yurdaydin C, Sollano J, et al. 2006. Entecavir for the treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology, 130:2039-49.
50. Shouval D, Hatzis G, Kitis G, et al. 2006. Continued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(-) hepatitis B patients (Study ETV-027). J Hepatol, 44:S182.
51. Tassopoulos NC, Volpes R, Pastore G, et al. 1999. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology, 29:889-96.
52. Tenney DJ, Levine SM, Rose RE, et al. 2004. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother, 48:3498-507.
53. Thongsawat S, Lai CL, Gane G, et al. 2006. Telbivudine displays consistent antiviral efficacy across patient subgroups for the treatment of chronic hepatitis B: results from the globe study. J Hepatol, 44:S49.
54. Villet S, Pichoud C, Ollivet A, et al. 2005. Sequential antiviral therapy leads to the emergence of multiple drug resistant hepatitis B virus. Hepatology, 42:581A.
55. Wong DKH, Cheung AM, O'Rourke K, et al. 1993. Effect of Alpha-Interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med, 119:312-23.
56. Yim HJ, Hussain M, Liu Y, et al. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology, 44:703-12.
57. Yurdaydin C, Sollano J, Hadziyannis SJ, et al. 2006. Entecavir results in continued virologic and biochemical improvement and HBeAg seroconversion through 96 weeks of treatment in lamivudine-refractory HBeAg (+) chronic hepatitis B patients (ETV-026). J Hepatol, 44:S36.